SynBioBeta Speaker
Drew Endy
Stanford University
Hoover Institution Fellow
Drew Endy is a science fellow and senior fellow (courtesy) at the Hoover Institution. He leads Hoover’s Bio-Strategy and Leadership effort, which focuses on keeping increasingly biotic futures secure, flourishing, and democratic. Professor Endy also researches and teaches bioengineering at Stanford University, where he is the Martin Family University Fellow in Undergraduate Education, senior fellow (courtesy) of the Freeman Spogli Institute for International Studies, and faculty codirector of degree programs for the Hasso Plattner Institute of Design.Professor Endy helped launch new undergraduate majors in bioengineering at both MIT and Stanford and the International Genetically Engineered Machine (iGEM) competition, which involves thousands of students annually. Endy has served on the US National Science Advisory Board for Biosecurity; the National Academies of Sciences, Engineering, and Medicine Committee on Science, Technology, and Law; the International Union for Conservation of Nature’s Synthetic Biology Task Force; and, briefly, the Pentagon’s Defense Innovation Board. He currently serves on the World Health Organization’s Advisory Committee on Variola Virus Research; the Organization for Economic Co-operation and Development’s (OECD) Global Forum on Technology’s synthetic biology task force; and the Defense Science Board’s Emerging Biotechnology and National Security Task Force. Endy earned his PhD from Dartmouth in biotechnology and biochemical engineering and has been recognized in Esquire magazine as one of the seventy-five most influential people of the twenty-first century.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Drew
This Year
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Institution Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Senior Director, Strategy and Operations
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
•
-
Business of Biology
Bio-Ready America: Advancing Bioliteracy to Power the U.S. Bioeconomy
As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.
Purchase Pass
Featuring
Drew Endy
Stanford University
Hoover Institution Fellow
Synthetic biology pioneer, co-founded iGEM and BioBricks.
Amy Jenkins
AstraZeneca
Senior Director, Strategy and Operations
Pandemic-response biotech leader; built rapid antibody platforms.
Stuart Sevier
IMI
President
Physicist turned science-media trust builder amplifying research stories.
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
